


CAR T-Cell Therapy Shapes The Cell And Gene Therapy Market Outlook

The Business Research Company's Cell And Gene Therapy Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, March 9, 2022 /EINPresswire.com/ --The global <u>cell and gene therapy</u> <u>market</u> overview show that chimeric antigen receptor (CAR) T-cell therapy is shaping the market. CAR T-cell therapy is a combination of cell and gene therapy in which T cells are collected



Cell And Gene Therapy Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

from the patient's blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors. These modified T cells with special structures (receptors) are reinfused into the patient. Then, the modified receptors of T cell help in targeting the surface antigen of the cancer cell that ultimately results in the killing of tumor cells in patients. In 2020, the US-FDA approved Bristol-Myers Squibb's two CAR-T cell therapies to treat lymphoma and multiple myeloma and is set to be launched. Currently, FDA approved CAR-T cell therapy treatments like Tisagenlecleucel for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in children and Axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

Steady investment and consolidation in cell and gene therapies contributed to the cell and gene therapy market growth. After recognizing the potential of the CGT market, 16 out of the 20 largest biopharma companies by revenue, added CGT products to their portfolio. For instance, Merck invested \$109 million in viral vector and gene therapy manufacturing in April 2020. Moreover, 12% of industrial clinical pipeline products and at least 16% of preclinical pipeline products consist of CGT. According to the cell and gene therapy market forecast, steady investment and consolidation in CGT production capacity led to an increase in production capacity and also contributed to the growth of the cell and gene therapy market.

Read more on the Global Cell And Gene Therapy Market Report: <u>https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-</u>

<u>report</u>

The global cell and gene therapy market size is expected to grow from \$6.58 billion in 2021 to \$8.57 billion in 2022 at a compound annual growth rate (CAGR) of 30.2%. The growth in the cell and gene therapy market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The gene and cell therapy market is expected to reach \$21.33 billion in 2026 at a CAGR of 25.6%.

Major players covered in the global cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio, and Fibrocell Science.

TBRC's global cell and gene therapy market report is segmented by product into cell therapy, gene therapy, by application into oncology, dermatology, musculoskeletal, others, by end-user into hospitals, ambulatory surgical centers, cancer care centers, wound care centers, others.

<u>Cell and Gene Therapy Global Market Report 2022</u> – By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Dermatology, Musculoskeletal), By End User (Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a cell and gene therapy market overview, forecast cell and gene therapy market size and growth for the whole market, cell and gene therapy market segments, geographies, cell and gene therapy market trends, cell and gene therapy market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Cell And Gene Therapy Market Report: <u>https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp</u>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Gene Editing Global Market Report 2022 – By Technology (CRISPR, TALEN, ZFN), By End Users (Biotechnology, Pharmaceutical, Contract Research Organization), By Application (Animal Genetic Engineering, Plant Genetic Engineering, Cell Line Engineering) – Market Size, Trends, And Global Forecast 2022-2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Cell Therapy Global Market Report 2022 – By Technique (Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy), By Therapy Type (Allogeneic Therapies, Autologous Therapies), By Application (Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing) – Market Size, Trends, And Global Forecast 2022-2026 Cellular Immunotherapy Global Market Report 2022 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer) – Market Size, Trends, And Global Forecast 2022-2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-marketreport

About The Business Research Company?

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <u>https://www.thebusinessresearchcompany.com/about-the-business-</u> research-company.aspx

Call us now for personal assistance with your purchase: Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Check out our: LinkedIn: <u>https://bit.ly/3b7850r</u> Twitter: <u>https://bit.ly/3b1rmjS</u> YouTube: <u>https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ</u> Blog: <u>http://blog.tbrc.info/</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/565064349

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.